NICE recommends further migraine prevention option
Galcanezumab (Emgality) is the second calcitonin gene-related peptide (CGRP) inhibitor to be approved for routine NHS prescribing in patients with chronic migraine.

This site is intended for healthcare professionals
Galcanezumab (Emgality) is the second calcitonin gene-related peptide (CGRP) inhibitor to be approved for routine NHS prescribing in patients with chronic migraine.